The 48 references in paper G. Baimakanova E., S. Avdeev N., Г. Баймаканова Е., С. Авдеев Н. (2014) “Диагностическая и прогностическая значимость концевого N-отрезка мозгового натрийуретического пептида (Nt-proBNP) при обострении хронической обструктивной болезни легких // Diagnostic and prognostic value of N-terminal-proB-type natriuretic peptide (NT-proBNP) in patient with acute exacerbations of COPD” / spz:neicon:pulmonology:y:2011:i:6:p:80-86

1
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2010 report is available onwww.goldcopd.com
(check this in PDF content)
2
Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418–1422.
(check this in PDF content)
3
Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
(check this in PDF content)
4
Lacoma A., Prat C., Andreo F., Domlnguez J.Biomarkers in the management of COPD. Eur. Respir. Rev. 2009; 18 (112): 96–104.
(check this in PDF content)
5
Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.
(check this in PDF content)
6
Oswald-Mammosser M., Weitzenblum E., Quoix E. et al. Prognostic factors in COPD patients receiving long-term oxygen therapy: importance of pulmonary artery pressure. Chest 1995; 107: 1193–1198.
(check this in PDF content)
7
Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–931.
(check this in PDF content)
8
Antonelli Incalzi R., Fuso L., De Rosa M. et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 2794–2800.
(check this in PDF content)
9
Mueller C., Breidthardt T., Laule-Kilian K. et al. The integration of BNP and NT-proBNP into clinical medicine. Swiss. Med. Wkly 2007; 137: 4–12.
(check this in PDF content)
10
Varpula M., Pulkki K., Karlsson S. et al. Predictive value of N-terminal pro-brain natriuretic peptide in severe sepsis and septic shock. Crit. Care Med. 2007; 35: 1277–1283.
(check this in PDF content)
11
Попова К.А., Авдеев СН. Значение натрийуретических пептидов в диагностике сердечной недостаточности и других заболеваний. Пульмонология 2006; 4: 106–111.
(check this in PDF content)
12
Doust J.A., Glasziou P.P., Pietrzak E. et al.A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch. Intern. Med. 2004; 164: 1978–1984.
(check this in PDF content)
13
Mueller T., Gegenhuber A., Poelz W. et al.Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin. Chim. Acta 2004; 341: 41–48.
(check this in PDF content)
14
Mueller T., Gegenhuber A., Poelz W. et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005; 91: 606–612.
(check this in PDF content)
15
Richards A.M., Nicholls M.G., Espiner E.A. et al.B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003; 107: 2786–2792.
(check this in PDF content)
16
Ray P., Arthaud M., Birolleau S. et al.Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J. Am. Geriatr. Soc. 2005; 53: 643–648.
(check this in PDF content)
17
Ishii J., Nomura M., Ito M. et al.Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin. Chim. Acta 2000; 301: 19–30.
(check this in PDF content)
18
Leuchte H.H., Holzapfel M., Baumgartner R.A. et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43: 764–770.
(check this in PDF content)
19
Stolz D., Christ-Crain M., Morgenthaler N.G. et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058–1067.
(check this in PDF content)
20
Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr. Rev. 2003; 24: 341–356.
(check this in PDF content)
21
Anthonisen N.R., Manfreda J., Warren C.P. et al.Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196–204.
(check this in PDF content)
22
Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chron. Dis. 1987; 40: 373–383.
(check this in PDF content)
23
Murray P.R., Washington J.A.Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clin. Proc. 1975; 50: 339–344.
(check this in PDF content)
24
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: Ninths Informational Supplement. Philadelphia, PA: NCCLS, 2001; vol. 21, (1).
(check this in PDF content)
25
Quanier P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (Suppl. 16): 5–40.
(check this in PDF content)
26
Swedberg K., Cleland J., Dargie H. et al. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur. Heart J. 2005; 26: 1115–1140.
(check this in PDF content)
27
Cheng V., Kazanagra R., Garcia A. et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Coll. Cardiol. 2001; 37: 386–391. Баймаканова Г.Е., Авдеев С.Н.Диагностическая и прогностическая значимость Nt-proBNP при обострении ХОБЛ
(check this in PDF content)
28
Stolz D., Breidthardt N., Christ-Crain M. et al. Use of B-type natriuretic peptide in the risk stratification of acute exacerbations of COPD. Chest 2008; 133: 1088–1094.
(check this in PDF content)
29
Weinfeld M.S., Chertow G.M., Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am. Heart J. 1999; 138: 285–290.
(check this in PDF content)
30
Ma K.K., Ogawa T., de Bold A.J.Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J. Mol. Cell. Cardiol. 2004; 36: 505–513.
(check this in PDF content)
31
Tanaka T., Kanda T., Takajashi T. et al.Interleukin-6 induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes. J. Int. Med. Res. 2004; 32: 57–61.
(check this in PDF content)
32
Tomaru Ki K., Arai M., Yokoyama T. et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J. Mol. Cell. Cardiol. 2002; 34: 649–659.
(check this in PDF content)
33
Court O., Kumar A., Parrillo J.E. et al.Clinical review: Myocardial depression in sepsis and septic shock. Crit. Care 2002; 6: 500–508.
(check this in PDF content)
34
Brueckmann M., Huhle G., Lang S. et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005; 26: 527–534.
(check this in PDF content)
35
Roch A., Allardet-Servent J., Michelet P. et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit. Care Med. 2005; 33: 1001–1007.
(check this in PDF content)
36
Charpentier J., Luyt C.-E., Fulla Y. et al.Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med. 2004; 32: 660–665.
(check this in PDF content)
37
Hoffmann U., Brueckmann M., Bertsch T. et al. Increased plasma levels of NT-proANP and NTproBNP as markers of cardiac dysfunction in septic patients. Clin. Lab. 2005; 51: 373–379.
(check this in PDF content)
38
Berendes E., Van Aken H., Raufhake C. et al. Differential secretion of atrial and brain natriuretic peptide in critically ill patients. Anesth. Analg. 2001; 93: 676–682.
(check this in PDF content)
39
Cuthbertson B.H., Patel R.R., Croal B.L. et al. B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia 2005; 60: 16–21.
(check this in PDF content)
40
Jefic D., Lee J.W., Jefic D. et al. Utility of B-type natriuretic peptide and N-terminal pro Btype natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest 2005; 128: 288–295.
(check this in PDF content)
41
Rudiger A., Gasser S., Fischler M. et al. Comparable increase of B-type natriuretic peptide and amino-terminal pro-Btype natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit. Care Med. 2006; 34: 2140–2144.
(check this in PDF content)
42
Chien J.-Y., Lin V.-S., Huang Y.-C. et al. Changes in B-type natriuretic peptide improve weaning outcome predicted by spontaneous breathing trial. Crit. Care Med. 2008; 36: 1421–1426.
(check this in PDF content)
43
Christ M., Thuerlimann A., Laule K. et al.Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea. Eur. J. Clin. Invest. 2007; 37: 834–841.
(check this in PDF content)
44
Nagaya N., Nishikimi T., Uematsu M. et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865–870.
(check this in PDF content)
45
Jelic S., Le Jemtel T.H.Diagnostic usefulness of B-type natriuretic peptide and functional consequences of muscle alterations in COPD and chronic heart failure. Chest 2006; 130: 1220–1230.
(check this in PDF content)
46
Grasso S., Leone A., De Michele M. et al.Use of N-terminal pro-brain natriuretic peptide to detect acute cardiac dysfunction during weaning failure in difficult-to-wean patients with chronic obstructive pulmonary disease. Crit. Care Med. 2007; 35: 96–105.
(check this in PDF content)
47
Abroug F., Ouanes-Besbes L., Nciri N. et al. Left heart dysfunction and severe exacerbation of COPD: Diagnostic performance of cardiac biomarkers. Am. J. Respir. Crit. Care Med. 2006; 174: 990–996.
(check this in PDF content)
48
Tung R.H., Camargo C.A., Krauser D. Amino-terminal probrain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. Ann. Emerg. Med. 2006; 48: 66–74. Информация об авторах
(check this in PDF content)